AAP
AMPH icon

Arax Advisory Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Arax Advisory Partners’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69K Buy
60
+27
+82% +$661 ﹤0.01% 3150
2025
Q4 		$884 Sell
33
-205
-86% -$5.28K ﹤0.01% 3515
2025
Q3 		$6.34K Buy
238
+157
+194% +$4.05K ﹤0.01% 2786
2025
Q2 		$1.86K Buy
+81
New +$2.01K ﹤0.01% 2592

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Arax Advisory Partners's AMPH Position: Q1 2026 in Review

Arax Advisory Partners increased its Amphastar Pharmaceuticals (AMPH) stake by 82% in Q1 2026, buying an estimated $661 and bringing the position to 60 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3150.

Arax Advisory Partners first reported a position in AMPH in Q2 2025 and has held it in 4 quarters since. The position peaked at $6.34K in Q3 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Arax Advisory Partners held 60 shares of Amphastar Pharmaceuticals worth $1.69K as of Q1 2026.
  • Arax Advisory Partners bought 27 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $661.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3150 holding.
  • Arax Advisory Partners first reported a position in Amphastar Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Amphastar Pharmaceuticals position peaked at $6.34K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.